Real-World tracking begins for rare genetic disorder treatment
NCT ID NCT07450664
Summary
This study is observing 200 patients with Prader-Willi syndrome who are taking the medication VYKAT XR. The main goal is to gather more information about the drug's safety and how patients respond during real-world use. It follows patients who are either starting the treatment or have already begun taking it, including some from previous research studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Sparrow Clinical Research Institute
Lansing, Michigan, 48912, United States
Conditions
Explore the condition pages connected to this study.